Vaccines against COVID-19 that have been developed in Japan are unlikely to be available until at least 2022, The Japan Times reported.
Only one company in Japan, AnGes, is conducting a trial of a vaccine, after a Phase II study started last month.
The company initially aimed to receive approval of the vaccine next spring, but the timing is now uncertain as it needs to conduct a trial covering several tens of thousands of people.
Meanwhile, Shionogi is developing a COVID-19 vaccine, with plans to launch a trial by the end of this year and conduct a large-scale study covering people in and outside Japan next year.
In addition, KM Biologics and Daiichi Sankyo Co. are set to launch a trial in March 2021, with ID Pharma expected to do so between March and May next year.
To read more NewsPoints articles, click here.